Copyright
©The Author(s) 2021.
World J Gastroenterol. Oct 21, 2021; 27(39): 6515-6521
Published online Oct 21, 2021. doi: 10.3748/wjg.v27.i39.6515
Published online Oct 21, 2021. doi: 10.3748/wjg.v27.i39.6515
Table 1 Clinical trials on the combination of poly(ADP-ribose) polymerase inhibitor with chemotherapy and immunotherapy
Identifier | Phase | iPARP | Title | Status |
NCT04548752 | II | Olaparib | Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients with Germline BRCA1 or BRCA2 Mutations | Recruiting |
NCT02890355 | II | Veliparib | Randomized Phase II Study of 2nd Line FOLFIRI vs Modified FOLFIRI With PARP Inhibitor ABT-888 (Veliparib) (NSC-737664) in Metastatic Pancreatic Cancer | Active, not recruiting |
NCT01585805 | II | Veliparib | A Randomized Phase II Study of Gemcitabine, Cisplatin +/- Veliparib in Patients with Pancreas Adenocarcinoma and known BRCA/ PALB2 Mutation (Part I) and a Phase II Single Arm Study of Single-Agent Veliparib in Previously Treated Pancreas Adenocarcinoma (Part II) | Active, not recruiting |
NCT01489865 | I/II | ABT-888 | A Phase I/II Study of ABT-888 in combination with 5-fluorouracil and Oxaliplatin (Modified FOLFOX-6) in Patients with Metastatic Pancreatic Cancer | Active, not recruiting |
NCT03404960 | I/II | Niraparib + Nivolumab Niraparib + Ipilimumab | PARPVAX: A Phase 1b/2, Open Label Study of Niraparib Plus either Ipilimumab or Nivolumab in Patients with Advanced Pancreatic Cancer whose disease has not progressed on Platinum-based Therapy | Recruiting |
NCT03553004 | II | Niraparib | Niraparib in Metastatic Pancreatic Cancer after previous Chemotherapy (NIRA-PANC) | Recruiting |
- Citation: Martínez-Galán J, Rodriguez I, Caba O. Importance of BRCA mutation for the current treatment of pancreatic cancer beyond maintenance. World J Gastroenterol 2021; 27(39): 6515-6521
- URL: https://www.wjgnet.com/1007-9327/full/v27/i39/6515.htm
- DOI: https://dx.doi.org/10.3748/wjg.v27.i39.6515